Show simple item record

dc.contributor.authorMilara, Javier
dc.contributor.authorCervera, Angela
dc.contributor.authorDiego-Damia, Alfredo de
dc.contributor.authorSanz, Celia
dc.contributor.authorJuan, Gustavo
dc.contributor.authorGavaldà, Amadeu
dc.contributor.authorMiralpeix, Montserrat
dc.contributor.authorMorcillo, Esteban
dc.contributor.authorCortijo, Julio
dc.date.accessioned2017-02-14T19:56:22Z
dc.date.available2017-02-14T19:56:22Z
dc.date.issued2016
dc.identifier.citationMILARA, Javier, et al. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients. Respiratory research, 2016, vol. 17, no 1, p. 145.ca_CA
dc.identifier.issn1465-9921
dc.identifier.issn1465-993X
dc.identifier.urihttp://hdl.handle.net/10234/166075
dc.description.abstractBackground: Inhaled corticosteroid (ICS) with long-acting beta-2 agonists is a well-documented combination therapy for chronic obstructive pulmonary disease (COPD) based on its additive anti-inflammatory properties. By contrast, the recommendation of ICS in combination with long-acting muscarinic antagonist (LAMA) is not evidence-based. In this study, neutrophils obtained from COPD patients were used to compare the anti-inflammatory effects of aclidinium bromide (a long-acting muscarinic antagonist) with corticosteroids and their potential additive effect. Methods: Human sputum and blood neutrophils were isolated from healthy individuals ( n = 37), patients with stable COPD ( n = 52) and those with exacerbated COPD ( n = 16). The cells were incubated with corticosteroid fluticasone propionate (0.1 nM – 1 μ M), aclidinium bromide (0.1 nM – 1 μ M) or a combination thereof and stimulated with 1 μ gof lipopolysaccharide/ml or 5 % cigarette smoke extract. Levels of the pro-inflammatory mediators interleukin-8, matrix metalloproteinase-9, CCL-5, granulocyte-macrophage colony-stimulating factor and interleukin-1 β were measured and the mechanisms of corticosteroid resistance evaluated at the end of the incubation. Results: The non-neuronal cholinergic system w as over-expressed in neutrophils fr om COPD patients, as evidenced by increases in the expression of muscarinic receptors (M2, M4 and M5), choline acetyltransferase and vesicular acetylcholine transporter. Aclidinium bromide demonstrated anti-inflamm atory effects on neutrophils from COPD patients, reversing their resistance to corticosteroids. Additive effects of c ombined aclidinium bromide and fluticasone propionate in blocking M2 receptor levels, inhibi ting phosphoinositide 3-kinase- δ and enhancing the glucocorticoid response element transcription factor were demonstrated and were accompanied by an increase in the corticosteroid-induced expression of anti-inflammatory-related genes. Conclusions: LAMAs potentiate the anti-inflammatory effects of corticosteroids in neutrophils from COPD patients in vitro, thus providing a scientific rationale for their use in combination with corticosteroids in the treatment of COPD.ca_CA
dc.description.sponsorShipThis work was supported by the grants SAF2014-55322-P (JC), FIS PI14/01733 (JM), SAF2015-65368-R (EM), CIBERES (CB06/06/0027), TRACE (TRA2009-0311; Spanish Government), and by research grants from the Regional Government Prometeo II/2013/014 (JC, EM, JM) “Generalitat Valenciana”. Funding entities did not contribute to the study design or data collection, analysis and interpretation nor to the writing of the manuscript.ca_CA
dc.format.extent14 p.ca_CA
dc.format.mimetypeapplication/pdfca_CA
dc.language.isoengca_CA
dc.publisherBioMed Centralca_CA
dc.relation.isPartOfRespiratory research, 2016, vol. 17, núm. 1ca_CA
dc.rights© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.ca_CA
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectNeutrophilsca_CA
dc.subjectCOPDca_CA
dc.subjectCorticosteroid resistanceca_CA
dc.subjectAclidinium bromideca_CA
dc.subjectNon-neuronal cholinergic systemca_CA
dc.titleNon-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patientsca_CA
dc.typeinfo:eu-repo/semantics/articleca_CA
dc.identifier.doihttp://dx.doi.org/10.1186/s12931-016-0467-8
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_CA
dc.relation.publisherVersionhttps://respiratory-research.biomedcentral.com/articles/10.1186/s12931-016-0467-8ca_CA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s). 2016
Open Access
This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Except where otherwise noted, this item's license is described as © The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.